Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.

Feb 20 (Reuters) - Eli Lilly (LLY.N), opens new tab is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million ...

Danish drugmaker Novo Nordisk and Eli Lilly currently dominate the market for weight-loss treatments with their injectable drugs. Novo is studying the pill version of its experimental drug ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...

As chief scientific officer at Eli Lilly, he's already done it once with the company's weekly shot, Zepbound. He's trying to do it again with a more convenient daily pill, then repeat the feat ...